X
Xiang Liu
Researcher at University of Melbourne
Publications - 30
Citations - 2241
Xiang Liu is an academic researcher from University of Melbourne. The author has contributed to research in topics: Medicine & Obstructive sleep apnea. The author has an hindex of 10, co-authored 15 publications receiving 2107 citations. Previous affiliations of Xiang Liu include Mental Health Research Institute & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Activation of memory circuits during cue-elicited cocaine craving
Steven Grant,Edythe D. London,David B. Newlin,Victor L. Villemagne,Xiang Liu,Carlo Contoreggi,Robert L. Phillips,Alane S. Kimes,Arthur Margolin +8 more
TL;DR: Correlations of metabolic increases in the dorsolateral prefrontal cortex, medial temporal lobe, and cerebellum with self-reports of craving suggest that a distributed neural network, which integrates emotional and cognitive aspects of memory, links environmental cues with cocaine craving.
Journal ArticleDOI
Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs Is Associated with Decreased Interstitial Aβ
Paul A. Adlard,Robert A. Cherny,Robert A. Cherny,David Finkelstein,David Finkelstein,Elisabeth Gautier,Elysia Robb,Mikhalina Cortes,Irene Volitakis,Xiang Liu,Jeffrey P. Smith,Keyla Perez,Keyla Perez,Katrina M. Laughton,Katrina M. Laughton,Qiao-Xin Li,Qiao-Xin Li,Susan A. Charman,Joseph A. Nicolazzo,Simon Wilkins,Simon Wilkins,Karolina Deleva,Toni Lynch,Gaik Beng Kok,Craig W. Ritchie,Rudolph E. Tanzi,Roberto Cappai,Roberto Cappai,Colin L. Masters,Colin L. Masters,Kevin J. Barnham,Kevin J. Barnham,Ashley I. Bush,Ashley I. Bush +33 more
TL;DR: The current data demonstrate that ionophore activity, inhibition of in vitro metal-mediated Abeta reactions, and blood-brain barrier permeability are indices that predict a potential disease-modifying drug for AD.
Journal ArticleDOI
Platinum-based inhibitors of amyloid-β as therapeutic agents for Alzheimer's disease
Kevin J. Barnham,Vijaya Kenche,Giuseppe D. Ciccotosto,David Smith,Deborah J. Tew,Xiang Liu,Keyla Perez,Greg A. Cranston,Timothy Johanssen,Irene Volitakis,Ashley I. Bush,Colin L. Masters,Anthony R. White,Jeffrey P. Smith,Robert A. Cherny,Roberto Cappai +15 more
TL;DR: The potent effect of the L-PtCl2 complexes identifies this class of compounds as therapeutic agents for AD and implies that the planar aromatic 1,10-phenanthroline ligands L confer some specificity for Aβ onto the platinum complexes.
Journal ArticleDOI
Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation
Margaret A. Park,Guo Zhang,Aditi Pandya Martin,Hossein A. Hamed,Clint Mitchell,Philip B. Hylemon,Martin R. Graf,Mohamed Rahmani,Kevin M. Ryan,Xiang Liu,Sarah Spiegel,James S. Norris,Paul B. Fisher,Steven Grant,Paul Dent +14 more
TL;DR: In this article, low doses of sorafenib and vorinostat interact in a synergistic fashion to kill carcinoma cells by activating CD95, and this drug combination is entering phase I trials.
Journal ArticleDOI
The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson’s disease
Lin W. Hung,Victor L. Villemagne,Victor L. Villemagne,Lesley Cheng,Nicki A. Sherratt,Scott Ayton,Anthony R. White,Peter J. Crouch,SinChun Lim,Su Ling Leong,Simon Wilkins,Jessica L George,Blaine R. Roberts,Chi L.L. Pham,Xiang Liu,Francis C. K. Chiu,David M. Shackleford,Andrew K. Powell,Colin L. Masters,Ashley I. Bush,Graeme O'Keefe,Janetta G. Culvenor,Roberto Cappai,Robert A. Cherny,Paul S. Donnelly,Andrew F. Hill,David Finkelstein,Kevin J. Barnham +27 more
TL;DR: The PET imaging agent CuII(atsm) improves motor and cognitive function in Parkinson’s disease.